Adma Biologics | ADMA - Sales Revenues

Stock Price
9.66
Daily Change
-0.17 -1.73%
Monthly
-38.98%
Yearly
-48.29%
Q2 Forecast
8.91

Adma Biologics reported $139.16M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Adma Biologics USD 139.16M 4.94M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Takeda JPY 1.19T 80B Dec/2025